<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Christoulas, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opinion on Therapeutic Patents</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">B ligand (RANKL)</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone formation</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone metastasis</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Osteoporosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor activator of nuclear factor-κ</style></keyword><keyword><style  face="normal" font="default" size="100%">Rheumatoid arthritis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-56849106456&amp;doi=10.1517%2f13543776.18.11.1265&amp;partnerID=40&amp;md5=2ddf3cf324b78bce5f649d4fc5ba8c7e</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">1265 - 1269</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Patent WO02095012A1 claims for the development of antibodies against receptor activator of nuclear factor-κ B ligand (RANKL) and immunologically functional fragments that neutralize RANKL. These molecules can be used to detect RANKL in biological samples, allowing the identification of pathological conditions in which RANKL alteration contributes to their pathophysiology. The use of anti-RANKL antibodies is of high importance in the treatment of bone disorders characterized by the stimulation of osteoclast function and subsequent bone loss. Postmenopausal and steroid-induced osteoporosis, myeloma bone disease, cancer bone metastases with lytic lesions and bone loss due to rheumatoid disorders (including rheumatoid arthritis) are candidates for anti-RANKL therapy, as RANKL is implicated in their pathogenesis. © 2008 Informa UK Ltd.</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><notes><style face="normal" font="default" size="100%">Cited By :2Export Date: 21 February 2017</style></notes></record></records></xml>